<DOC>
	<DOCNO>NCT00863148</DOCNO>
	<brief_summary>Clofarabine know strong anti-tumor effect Fludarabine show efficacy treat aggressive acute leukemia . In addition , evidence well-tolerated manageable side effect especially elderly patient . Thus , replace Fludarabine Clofarabine reduce intensity transplant regimen may provide regimen increase anti-tumor activity without add significant risk toxicity.The purpose study evaluate efficacy safety clofarabine combination IV busulfan ATG backbone reduce intensity condition regimen allogeneic stem cell transplantation treatment patient high-risk MDS/AML ALL eligible conventional standard myeloablative allo-SCT .</brief_summary>
	<brief_title>Allogeneic Stem Cell Transplant With Clofarabine , Busulfan Antithymocyte Globulin ( ATG ) Adult Patients With High-risk Acute Myeloid Leukemia/Myelodysplastic Syndromes ( AML/MDS ) Acute Lymphoblastic Leukemia ( ALL )</brief_title>
	<detailed_description />
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<criteria>Age 18 65 For patient young 50 year , consindication use standard myeloablative conditioning ( history hematopoietic stem cell transplantation autologous allogeneic , presence comorbidities medical history make prohibitive term toxicity use chemotherapy / high dose radiotherapy judge refer physician ) MDS , ALL AML high risk , WHO THE biphenotypicScore &lt; 2 Any primary diagnosis highrisk MDS/AML ALL eligible treatment reduce intensity conditioning ( RIC ) allogeneic hematopoietic stem cell transplantation ( alloSCT ) Suitable donor available ( relate matched unrelated ) Cardiac : LV Ejection Fraction ≥ 50 % MUGA Echocardiogram . Pulmonary : FEV1 FVC ≥ 50 % predict , DLCO ( correct hemoglobin ) ≥ 50 % predicted Adequate renal hepatic function Performance status : Karnofsky ≥ 70 % Informed consent sign patient prior enrolment Age &lt; 18 Age &gt; 65 Known hypersensitivity clofarabine excipients Other hematologic malignancy ALL , AML MDS Patients prior standard allogeneic HSCT grade &gt; 2 aGvHD Prior standard allogeneic transplantation &lt; 2 month Contraindication one drug RIC regimen . Patient &gt; 3 treatment line prior inclusion Pregnant lactating female Patient HIV+ , Hep B+ , Hep C+ Uncontrolled systemic infection Performance Status Score ECOG &gt; 2 Known central nervous system involvement AML ALL Uncontrolled active infection kind bleed Any severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver organ system may place patient undue risk undergo agent include condition regimen . For patient young 50 year , possibly indicate standard myeloablative conditioning</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>MDS</keyword>
	<keyword>AML</keyword>
	<keyword>ALL</keyword>
	<keyword>RIC</keyword>
	<keyword>clofarabine</keyword>
	<keyword>allo-HSCT</keyword>
	<keyword>high-risk MDS/AML</keyword>
</DOC>